Women – especially teen girls and young women living in sub-Saharan Africa – are disproportionately impacted by <a ...

Grace Place: 2024 Haus of Gingerbread Haus of Gingerbread, benefitting the youth of Grace Place, is even bigger and better ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

In Uganda, women and girls are more affected by HIV. Out of 1.4 million people living with the disease, 860 000 are women and ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

The company’s shares closed yesterday at $8.91. Don't Miss our Black Friday Offers: Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Oruka Therapeutics, and Gilead ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Merck, Bristol Myers and Gilead Sciences have all invested heavily in TIGIT, as have smaller biotechnology companies like ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...

Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc.

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) and Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two ...